7150-03-0

Basic information

• Product Name: 6-amino-5-bromo-3-methylpyrimidine-2,4(1H,3H)-dione
• CAS NO: 7150-03-0
• Molecular Formula: C₅H₆BrN₃O₂
• Molecular Weight: 220.024
• Mol File: 7150-03-0.mol
• Article Data: 5

Chemical Properties

• Density: 1.868g/cm³
• Refractive Index: 1.618
• CAS DataBase Reference: 6-amino-5-bromo-3-methylpyrimidine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 6-amino-5-bromo-3-methylpyrimidine-2,4(1H,3H)-dione(7150-03-0)
• EPA Substance Registry System: 6-amino-5-bromo-3-methylpyrimidine-2,4(1H,3H)-dione(7150-03-0)

Safety Data

• Hazardous Substances Data: 7150-03-0(Hazardous Substances Data)

Upstream product

• 21236-97-5 3-methyl-6-aminouracil 

Downstream Products

• 611-59-6 paraxanthine 
• 55782-76-8 N-(6-amino-3-methyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-N-methyl-formamide 

Relevant articles and documents

Pyrimidine-4 (3H)-ketone heterocyclic compound, preparation method thereof and application of pyrimidine-4 (3H)-ketone heterocyclic compound in medicine

The invention relates to pyrimidine-4 (3H)-ketone heterocyclic compounds suitable for inhibiting or regulating SHP2, a preparation method of the pyrimidine-4 (3H)-ketone heterocyclic compounds and application of the pyrimidine-4 (3H)-ketone heterocyclic compounds in medicine. Specifically, the invention relates to a compound as shown in a general formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, a method for treating and/or preventing related diseases mediated by SHP2, especially cancers by using the compound or the pharmaceutically acceptable salt thereof, and a preparation method of the compound or the pharmaceutically acceptable salt thereof. The invention also relates to application of the compound or the pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof in preparation of drugs for treating and/or preventing SHP2-mediated related diseases. Wherein each substituent in the general formula (I) is as defined in the specification.

Compound serving as SHP2 inhibitor and application thereof

The invention belongs to the field of medical chemistry, relates to a compound serving as an SHP2 inhibitor and an application of the compound, and particularly provides a compound shown in a formula (I) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug of the compound, processes for the preparation, pharmaceutical compositions containing these compounds and the use of these compounds or compositions for the treatment of SHP2 mediated diseases.

COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2

The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.